MOS Prebiotic Potential in Older Adults

University of Florida

Status

Active, not recruiting

Conditions

Healthy

Treatments

Dietary Supplement: Mannooligosaccharides yeast extract

Study type

Interventional

Funder types

Other

Identifiers

NCT05939336

IRB202301046

Details and patient eligibility

About

Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.

Full description

Novel prebiotics with specific microbiome targets and without adverse gastrointestinal symptoms are needed for the exploration of health benefits. This is a 3-week, open-label pilot study designed to evaluate the effect of 15 g per day of yeast-derived mannooligosaccharides on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites.

Enrollment

40 estimated patients

Sex

All

Ages

50 to 99 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Adults 50-99 years of age.
Able to provide written informed consent in English.
Willingness to complete all study procedures
Healthy or diagnoses with Parkinson's or multiple system atrophy

Exclusion criteria

Yeast allergy.
Self-reported kidney disease.
Elite athletes or long-distance runners.
Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening visit.
Current use of laxatives or antidiarrheal medications.
Use of other investigational products within 3 months of the screening visit.
Previously or currently being treated for any intestinal disease or condition, including IBS, Crohn's disease, ulcerative colitis, celiac disease, or gastrointestinal cancer (self-report).
Previous gastrointestinal surgery (e.g., gastric bypass, fundoplication, bowel resection)
Current cancer treatment
Currently pregnant